Verrica Pharmaceuticals INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Caligan Partners LP, a significant shareholder, has appointed Dr. Charles Frantzreb to the Board of Directors of Verrica Pharmaceuticals Inc., effective December 26, 2025.
NASDAQ
SCHEDULE 13D/A: Manning Boosts Verrica Stake to 49.9% After Unit Purchases
Paul B. Manning and affiliated entities increased their beneficial ownership in Verrica Pharmaceuticals Inc. to 49.9% through recent purchases of common stock and warrants.
NASDAQ
Caligan Partners LP and David Johnson have acquired a 9.99% beneficial ownership in Verrica Pharmaceuticals Inc. through a private placement, securing a board seat and expressing belief in the company's undervaluation.